,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2020-06-04 05:49:00,Shares of Veeva Systems (NYSE: VEEV) recently rose to all-time highs after its first-quarter earnings report impressed investors.,0.9397876858711243,0.0232717152684927,0.03694058582186699,positive,0.9165159463882446
1,2020-06-04 05:49:00,"The life science cloud services provider's revenue rose 38% annually to $337.1 million, beating estimates by $12.3 million.",0.9551758170127869,0.022969473153352737,0.021854715421795845,positive,0.9322063326835632
2,2020-06-04 05:49:00,"Veeva's net income under generally accepted accounting principles (GAAP) rose 18% to $86.6 million, while its non-GAAP net income grew 34% to $105.2 million, or $0.66 per share, beating expectations by $0.07.",0.957239031791687,0.02328033745288849,0.019480735063552856,positive,0.9339587092399597
3,2020-06-04 05:49:00,"Veeva's growth was impressive, but does this stock still have room after rallying roughly 230% over the past three years?",0.9030721187591553,0.021158937364816666,0.07576889544725418,positive,0.8819131851196289
4,2020-06-04 05:49:00,Veeva provides cloud-based services for life science and healthcare companies.,0.03526132553815842,0.004706730134785175,0.9600319266319275,neutral,0.030554596334695816
5,2020-06-04 05:49:00,"Its core services help top pharmaceutical companies like GlaxoSmithKline and AstraZeneca track customer relationships, industry regulations, clinical trials, prescribing habits, and other data.",0.0998472049832344,0.005469536874443293,0.8946832418441772,neutral,0.09437766671180725
6,2020-06-04 05:49:00,"Veeva enjoys a first-mover advantage in this niche space, doesn't face any meaningful competitors, and has seen demand for its services surge as competition escalates between drugmakers.",0.9214102029800415,0.015828540548682213,0.06276117265224457,positive,0.9055816531181335
7,2020-06-04 05:49:00,Its platform is deeply integrated into salesforce.com's (NYSE: CRM) marketing and service clouds.,0.2171611785888672,0.00622407253831625,0.7766147255897522,neutral,0.21093711256980896
8,2020-06-04 05:49:00,The COVID-19 crisis isn't disrupting demand for Veeva's services.,0.04378540813922882,0.6670304536819458,0.2891841232776642,negative,-0.6232450604438782
9,2020-06-04 05:49:00,"Instead, it's likely reinforcing the importance of those services as companies rush to develop new treatments and vaccines for the pandemic.",0.6447649598121643,0.015552714467048645,0.33968234062194824,positive,0.6292122602462769
10,2020-06-04 05:49:00,"That's why Veeva's revenue and net income growth both accelerated during the first quarter, which bore the full impact of COVID-19:

COVID-19 mainly affected Veeva's two recent acquisitions -- events management platform Physicians World and patient analytics platform Crossix -- which faced suspensions of in-person events and declining ad revenue throughout the crisis.",0.02013613097369671,0.9578374028205872,0.022026456892490387,negative,-0.9377012848854065
11,2020-06-04 05:49:00,"Veeva's Vault business -- a cloud enterprise content management platform for life sciences -- also struggled with modestly lower spending from pre-commercial small-to-medium businesses, contact research organizations, medical device makers, and cosmetics companies.",0.030483854934573174,0.9410736560821533,0.02844255231320858,negative,-0.9105898141860962
12,2020-06-04 05:49:00,"However, the broader life sciences industry remained stable, and usage of Veeva's commercial cloud services rose as customers enabled their field reps to maintain virtual contact with doctors.",0.9484868049621582,0.017973201349377632,0.033539995551109314,positive,0.9305136203765869
13,2020-06-04 05:49:00,"As a result, the net impact of COVID-19 on Veeva's overall business was relatively minor.",0.013599616475403309,0.046472400426864624,0.9399279356002808,neutral,-0.03287278488278389
14,2020-06-04 05:49:00,"Veeva expects its second-quarter revenue to rise between 27% and 28% annually, and for its non-GAAP EPS to rise between 26% and 28%.",0.9365443587303162,0.01340841967612505,0.05004722625017166,positive,0.9231359362602234
15,2020-06-04 05:49:00,"For the full year, it expects the COVID-19 challenges to reduce the top end of its revenue guidance by just $10 million -- to a range of $1.38 billion to $1.395 billion -- which still implies growth between 25% and 26% compared to fiscal 2020.",0.018388010561466217,0.9644536972045898,0.01715824194252491,negative,-0.9460656642913818
16,2020-06-04 05:49:00,It expects its full-year non-GAAP EPS to rise between 14% and 16%.,0.9414499402046204,0.014695684425532818,0.043854374438524246,positive,0.9267542362213135
17,2020-06-04 05:49:00,Veeva also reiterated its goal of generating $3 billion in annual revenue by fiscal 2025.,0.7044251561164856,0.010847249999642372,0.2847276031970978,positive,0.6935778856277466
18,2020-06-04 05:49:00,Veeva's subscription revenue rose 36% annually during the quarter and accounted for 80% of its top line.,0.9336732625961304,0.014248980209231377,0.05207783728837967,positive,0.919424295425415
19,2020-06-04 05:49:00,"The segment's non-GAAP gross margin dipped annually from 85.2% to 85%, partly due to its acquisitions of Physicians and Crossix, which should nonetheless strengthen its ecosystem over the long run.",0.030795861035585403,0.9615402817726135,0.007663881406188011,negative,-0.9307444095611572
20,2020-06-04 05:49:00,"The rest of Veeva's revenue came from its ""professional services and other"" business, where its non-GAAP gross margin also contracted from 31.1% to 30.5%.",0.20506761968135834,0.7750686407089233,0.0198636706918478,negative,-0.5700010061264038
21,2020-06-04 05:49:00,Its total non-GAAP gross margin contracted from 74.9% to 74.2%.,0.2791666090488434,0.7063849568367004,0.014448441565036774,negative,-0.42721834778785706
22,2020-06-04 05:49:00,"Despite those gross margin headwinds, Veeva's non-GAAP operating margin still expanded from 38.2% to 38.5%, as its travel expenses declined during the COVID-19 crisis.",0.95587557554245,0.023379486054182053,0.020744940266013145,positive,0.9324960708618164
23,2020-06-04 05:49:00,Those tailwinds should persist throughout the crisis and enable Veeva to remain consistently profitable by both non-GAAP and GAAP measures.,0.9330043792724609,0.014572814106941223,0.05242273211479187,positive,0.9184315800666809
24,2020-06-04 05:49:00,"However, Veeva currently trades at nearly 90 times forward earnings -- which makes it pricey relative to its earnings growth potential.",0.05509016290307045,0.40478771924972534,0.5401220917701721,neutral,-0.3496975600719452
25,2020-06-04 05:49:00,So should you buy Veeva's stock at its all-time high?,0.2110556662082672,0.021286658942699432,0.7676576375961304,neutral,0.18976899981498718
26,2020-06-04 05:49:00,Veeva has a resilient business and a wide moat.,0.7455127835273743,0.012151390314102173,0.24233587086200714,positive,0.7333613634109497
27,2020-06-04 05:49:00,"It's barely affected by COVID-19 and other macro headwinds, doesn't face many direct competitors, and serves a growing niche market with plenty of spending power.",0.4116498529911041,0.012499101459980011,0.5758510828018188,neutral,0.3991507589817047
28,2020-06-04 05:49:00,"Investors can nibble on Veeva at these levels, since it arguably deserves its premium valuation if it can eventually generate $3 billion in annual revenue, but investors could get a better buying opportunity if the macro headwinds finally catch up to this euphoric market.",0.8426094055175781,0.044753964990377426,0.11263661086559296,positive,0.7978554368019104
29,2020-06-04 05:49:00,"10 stocks we like better than Veeva Systems

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.",0.12699975073337555,0.025114860385656357,0.8478853702545166,neutral,0.1018848866224289
30,2020-06-04 05:49:00,"After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.",0.46925464272499084,0.07301506400108337,0.4577302634716034,positive,0.39623957872390747
31,2020-06-04 05:49:00,"*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Veeva Systems wasn't one of them!",0.20886248350143433,0.015013301745057106,0.7761241793632507,neutral,0.19384917616844177
32,2020-06-04 05:49:00,That's right -- they think these 10 stocks are even better buys.,0.8146857619285583,0.02307075634598732,0.16224350035190582,positive,0.7916150093078613
33,2020-06-04 05:49:00,Leo Sun owns shares of GlaxoSmithKline.,0.01239218283444643,0.009491105563938618,0.9781167507171631,neutral,0.0029010772705078125
34,2020-06-04 05:49:00,The Motley Fool owns shares of and recommends Salesforce.com and Veeva Systems.,0.03005971759557724,0.018141884356737137,0.9517984390258789,neutral,0.011917833238840103
35,2020-06-04 05:49:00,The Motley Fool has a disclosure policy.,0.016547124832868576,0.017303891479969025,0.9661489725112915,neutral,-0.0007567666471004486
